Literature DB >> 27712765

Clinical Trials of Aspirin Treatment After Desensitization in Aspirin-Exacerbated Respiratory Disease.

Marek L Kowalski1, Aleksandra Wardzyńska2, Joanna S Makowska3.   

Abstract

The clinical efficacy of aspirin treatment after desensitization in patients with respiratory disease exacerbated by nonsteroidal anti-inflammatory drugs has been documented in observational studies and in double-blind placebo-controlled trials. There is no general agreement with regard to the optimal maintenance dose or duration of treatment with acetylsalicylic acid after desensitization, thus further studies are necessary to offer clear guidelines to clinicians. This article summarizes data from noncontrolled, active-control, and placebo-controlled trials assessing clinical effectiveness and reporting on safety of treatment with acetylsalicylic acid in desensitized patients with respiratory disease exacerbated by nonsteroidal anti-inflammatory drugs.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Aspirin desensitization; Aspirin hypersensitivity; Asthma; Chronic rhinosinusitis; NSAIDs-exacerbated respiratory disease; Nonsteroidal anti-inflammatory drugs

Mesh:

Substances:

Year:  2016        PMID: 27712765     DOI: 10.1016/j.iac.2016.06.007

Source DB:  PubMed          Journal:  Immunol Allergy Clin North Am        ISSN: 0889-8561            Impact factor:   3.479


  3 in total

1.  Regular Treatment With Aspirin 300 mg/day After Desensitization in Patients With N-ERD: 12-Year Results.

Authors:  Saltuk Buğra Kaya; Mehmet Erdem Çakmak; Ebru Damadoğlu; Gül Karakaya; Ali Fuat Kalyoncu
Journal:  Turk Thorac J       Date:  2021-09

Review 2.  Emerging Biomarkers Beyond Leukotrienes for the Management of Nonsteroidal Anti-inflammatory Drug (NSAID)-Exacerbated Respiratory Disease.

Authors:  Hyo-In Rhyou; Young-Hee Nam; Hae-Sim Park
Journal:  Allergy Asthma Immunol Res       Date:  2022-03       Impact factor: 5.764

3.  Clinical and Immunological Efficacy of Aspirin Desensitization in Nasal Polyp Patients with Aspirin-Exacerbated Respiratory Disease.

Authors:  Negar Mortazavi; Hossein Esmaeilzadeh; Mohammad Abbasinazari; Delara Babaie; Soheila Alyasin; Hesamodin Nabavizadeh; Elmira Esmailzadeh
Journal:  Iran J Pharm Res       Date:  2017       Impact factor: 1.696

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.